Clinical Trials Logo

Hematopoietic Organs; Disorder clinical trials

View clinical trials related to Hematopoietic Organs; Disorder.

Filter by:
  • None
  • Page 1

NCT ID: NCT06075563 Recruiting - Clinical trials for Hematopoietic Organs; Disorder

Total Lymphoid Irradiation as Conditioning for Pediatric Haploidentical Hematopoietic Stem Cell Transplantation

Start date: May 29, 2023
Phase: N/A
Study type: Interventional

In this comparative study, the investigators aim to compare prospective pediatric patients who receive total lymphoid irradiation (TLI) using tomotherapy with age- and disease-matched controls who receive conventional total body irradiation (TBI) as part of conditioning for haploidentical hematopoietic stem cell transplantation (HSCT) for both malignant and non-malignant diseases. The investigators shall evaluate graft failure-free, graft-versus-host disease (GVHD)-free survival, overall survival, frequency of rejection, GVHD, relapse of malignancy, adverse effects and post-transplant immunoreconstitution.

NCT ID: NCT06034535 Recruiting - Clinical trials for Hematopoietic Organs; Disorder

CD62L Depleted Donor Lymphocyte Infusion With T Cell Depleted Haploidentical Hematopoietic Stem Cell Transplantation

Start date: September 1, 2023
Phase: Phase 2
Study type: Interventional

In this clinical trial, the investigators aim to apply CD62L depleted donor lymphocyte infusion (DLI) together with in vitro T cell depleted haploidentical hematopoietic stem cell transplantation (HSCT) to treat patients with malignant or non-malignant disease in need of HSCT. The investigators shall evaluate the graft failure-free, graft-versus-host disease (GVHD)-free survival at one year, frequency of adverse events and post-transplant complications, and immunoreconstitution.

NCT ID: NCT01010867 Completed - Clinical trials for Hematopoietic Organs; Disorder

Probiotic Use in Children Undergoing Hematopoietic Stem Cell Transplantation (HSCT)

Start date: February 2010
Phase: Phase 1
Study type: Interventional

Primary Objective: 1. To evaluate the safety of orally administered Lactobacillus plantarum strains 299 and 299v, a probiotic, in patients undergoing allogeneic myeloablative HSCT, as measured by incidence of Lactobacillus plantarum bacteremia. Secondary Objectives: 1. To investigate the feasibility of administering Lactobacillus plantarum 299 and 299v to children and adolescents undergoing HSCT. 2. To describe the overall incidence of bacteremia in HSCT patients who have been administered Lactobacillus plantarum. 3. To describe the overall incidence of acute graft versus host disease (GVHD) in HSCT patients who have been administered Lactobacillus plantarum.